Monograph Details
|
|
Neoplasms
> Antimicrotubule agents
|
|
Vinblastine for injection |
| Manufacturer |
|
Bedford Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antimicrotubule agent. |
| Generic Name |
|
Vinblastine (as sulfate) 10mg/vial; lyophilized pwd for IV inj or infusion after reconstitution. |
| Also |
|
• Vinblastine injection
|
| Indications |
|
Frequently responsive: palliative treatment of generalized Hodgkin's disease, lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides, advanced carcinoma of the testis, Kaposi's sarcoma, Letterer-Siwe disease. Less frequently responsive: choriocarcinoma resistant to other chemotherapy; breast cancer, unresponsive to endocrine surgery and hormonal therapy. |
| Children |
|
See literature. IV use only. Letterer-Siwe disease: initially 6.5mg/m2. Hodgkin's disease: initially 6mg/m2. Testicular germ cell carcinomas: initially 3mg/m2. Adjust dose according to hematologic tolerance. |
| Adults |
|
See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL. |
| Contraindications |
|
Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first). |
| Precautions |
|
For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended. |
| Interactions |
|
May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin. |
| Adverse Reactions |
|
Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm. |
| How Supplied |
Pwd—10
Soln—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
